Is topical testosterone gel effective when applied to the scrotum?

Scrotal Application of Testosterone Cream: Efficacy and Evidence

Yes, testosterone cream/gel applied to the scrotum is highly effective and achieves therapeutic testosterone levels more rapidly and at lower doses than non-scrotal application, though it is not FDA-approved for this route and carries specific monitoring requirements.

Enhanced Absorption Through Scrotal Skin

Scrotal skin demonstrates markedly superior testosterone absorption compared to other body sites. The scrotal route achieves therapeutic serum testosterone concentrations (>400 ng/dL) within 2 hours of application, with sustained levels exceeding 1200 ng/dL maintained beyond 6 hours 1. This rapid absorption occurs because scrotal skin is thin and has exceptionally high steroid permeability 2.

• Dose requirements are substantially lower with scrotal application: A 25 mg dose applied to scrotal skin maintains physiological testosterone levels for 16 hours, whereas non-scrotal routes typically require 50–100 mg daily 2, 3.
• Peak serum testosterone occurs at 1.9–2.8 hours post-application with scrotal delivery, demonstrating dose-dependent pharmacokinetics (p<0.0001) 2.
• Historical FDA-approved scrotal patches (Testoderm) validated this route: These patches increased testosterone to low-normal range with peak levels at 3–5 hours after application, confirming the viability of scrotal delivery 4.

Critical Distinction: FDA Labeling vs. Clinical Practice

Current FDA-approved testosterone gels (1% and 1.62% formulations) explicitly prohibit scrotal application and mandate use only on shoulders and upper arms 5. The FDA labeling states: "Do not apply testosterone gel 1.62% to any other parts of the body including the abdomen, genitals, chest, armpits (axillae), or knees" 5.

• Off-label scrotal application is practiced but lacks FDA approval: Compounded testosterone creams are commonly prescribed for scrotal use in clinical practice, but this represents off-label prescribing 1.
• The prohibition stems from transfer risk concerns, not efficacy: FDA restrictions focus on preventing secondary exposure to women and children through skin-to-skin contact, which is heightened with genital application 5.

Dihydrotestosterone (DHT) Elevation: A Key Consideration

Scrotal application produces markedly elevated DHT levels due to high 5α-reductase activity in scrotal skin. Serum DHT reaches peak concentrations of 1.2 ng/mL (4.1 nmol/L) at approximately 4.9 hours—delayed 2 hours after peak testosterone—but this increase is time-dependent rather than dose-dependent 2.

• Historical scrotal patches generated "quite high" DHT levels that raised questions about long-term safety, though the clinical significance remains uncertain 4.
• Estradiol levels do not change significantly with scrotal testosterone application, contrasting with the DHT elevation 2.

Monitoring Requirements for Scrotal Application

If scrotal application is used off-label, monitoring must follow standard testosterone therapy protocols with heightened attention to DHT-related effects:

• Measure serum testosterone after ≥1 week of continuous use to assess steady-state levels, targeting the mid-normal range of 400–700 ng/dL 6, 7.
• Check hematocrit at baseline, 3–6 months, and annually; discontinue immediately if hematocrit exceeds 54% 6, 8, 7.
• Prostate surveillance (men ≥40 years) requires baseline and 3–6 month PSA and digital rectal exam, then annually; refer to urology if PSA rises >1.4 ng/mL within 12 months 6, 7.
• Consider monitoring DHT levels given the unique elevation with scrotal application, though specific thresholds are not established in guidelines 4, 2.

Practical Application Technique

For off-label scrotal use, the following technique optimizes absorption while minimizing transfer risk:

• Apply a thin layer to clean, dry scrotal skin using the palm of the hand to spread the cream evenly 1, 3.
• Wash hands immediately with soap and water after application 6, 5.
• Cover the application site with clothing (underwear) after the gel dries, and wash the scrotal area thoroughly before any skin-to-skin contact 5.
• Avoid swimming or washing the area for at least 2 hours to ensure adequate absorption 5.

Common Pitfalls to Avoid

• Do not use FDA-approved commercial gels (AndroGel, Testim, Fortesta) on the scrotum: These products are formulated and labeled exclusively for non-scrotal use; scrotal application violates FDA labeling and increases liability 5.
• Compounded testosterone creams are the appropriate formulation for scrotal application when this route is chosen 1.
• Failure to counsel on transfer risk is a critical error: Secondary exposure to women and children through unwashed scrotal skin contact can cause virilization 5.
• Ignoring DHT elevation may miss prostate-related adverse effects: The high DHT levels unique to scrotal application warrant closer prostate monitoring than non-scrotal routes 4, 2.

Alternative: Non-Scrotal Transdermal Routes

If avoiding off-label use is preferred, FDA-approved non-scrotal gels provide effective testosterone replacement with lower DHT elevation:

• Apply 40.5–81 mg daily to shoulders and upper arms (for 1.62% gel formulations), targeting mid-normal testosterone levels 9, 5.
• Non-scrotal application maintains stable DHT within normal range, avoiding the supraphysiologic DHT seen with scrotal delivery 4.